Introduction
It is said that the prostate was histologically acknowledged as an independent organ for the first time in the mid-nineteenth century. No organ termed the prostate is indicated even in the world-renowned drawing of anatomy by Leonard da Vinci (1452 -1519). It was in 1941 that androgen depletion therapy (ADT) was reported as effective against prostate cancer. For this achievement, Dr. Huggins received a Nobel Prize 25 years later in 1966. At that time, most patients with prostate cancer who received ADT were in progressive stage. As such, Dr. Huggins himself observed that recurrence was noted in many cases after several years of remission. ADT was therefore classified as a palliative treatment. Since PSA was discovered in 1979, the rate of detection of early-stage prostate cancer has rapidly improved. Subsequently, in 1983, the method of anatomical prostatectomy was reported by Walsh, and established the concept of radical treatment of prostate cancer. To be more precise, it became accepted that localized prostate cancer (LPC) and locally advanced prostate cancer (LAPC), the rate of detection of which sharply increased thanks to PSA screening, should be aggressively treated by radical methods including prostatectomy and radiotherapy. However, the conclusion that ADT is a palliative method of treatment reached half a century ago is still accepted at present.
As a result, this concept has been applied even to LPC and LAPC, and few careful clinical studies have been performed 1) . Despite the progress in ADT, including the establishment of theoretical grounds for maximal androgen blockade (or combined androgen blockade; MAB or CAB) and the development of a new nonsteroidal antiandrogen preparation, there has been little change in the concept of ADT as a palliative method of treatment of progressive prostate cancer, either.
(II)
Current status of ADT The Prostate Cancer Treatment Guideline was published by the Japanese Urological Association in 2006 2) . As a member in charge of the drug therapy section of this edition, the author would like to report the current status of ADT by citing the abstract of the overview of this section.
"At present, there is no chemotherapy superior to endocrine therapy for the treatment of prostate cancer. Though the proximal effects of various endocrine therapies are remarkable, there is a limit to their indication since the effects of treatment persist for only for 2 to 3 years in progressive cases and because of the onset of sex-related adverse reactions including erectile dysfunction (ED) and decreased libido.
The most generally applicable endocrine therapy is monotherapy with luteinizing hormone-releasing hormone (LH-RH) agonist or antiandrogen preparation, or concomitant treatment with these 2 drugs. In treatment with LH-RH agonist, concomitant administration of an antiandrogen preparation should be considered if urinary tract obstruction caused by flare-up phenomenon associated with a transient increase in testosterone in the initial stage of administration, ostealgia due to a metastatic lesion, spinal compression, etc. are anticipated. The efficacy of LH-RH agonist is considered equivalent to that of castration. However, the efficacy of monotherapy with antiandrogen preparation is reported to be less than that of LH-RH, though no significant difference was observed. On the other hand, antiandrogen preparations induce fewer sex-related adverse reactions. Monotherapy with nonsteroidal antiandrogen preparations has therefore been reported to be useful, depending on patient status. When the usefulness of bicalutamide as auxiliary therapy was investigated in LPC or LAPC in patients undergoing radical surgery, radiotherapy, and cautious observation of clinical course, prolongation of PSA doubling time and decrease in objective risk of progression were observed. At present, a large-scale investigation of prolongation of survival period is proceeding. In another investigation, whether chemo-endocrine therapy is more effective in treating Stage IV prostate cancer than endocrine monotherapy alone is being examined.
The down-staging effect of neo-adjuvant hormonal therapy (NHT) is manifested as a decrease in frequency of cases with a positive resected stump or lymph node metastasis.
Many randomized controlled studies (RCT) have confirmed the efficacy of NHT.
However, since no clear evidence that NHT can improve survival rate has been obtained, the results of analysis of long-term prognosis in each of these trials are awaited.
Endocrine therapy is opted for in treating stage III-IV prostate cancer, and life-prolonging effects of it have been observed. Endocrine therapy is sometimes performed in combination with surgery and radiotherapy in stage III cases. Particularly since the report on the results of a RCT that survival period was prolonged more by concomitant radiotherapy and endocrine therapy than by radiotherapy alone, there has been much expectation regarding the efficacy of concomitant treatment. However, there are problems in this regard, including the selection of appropriate patients, the appropriate time for initiation of endocrine therapy, the duration of treatment, and others. In general, the standard treatment for progressive prostate cancer with metastasis is ADT by surgical or medical castration. Since 40% of the androgen present in prostate gland cells appears to be derived from the adrenals, MAB was found to be useful due to inhibition of androgen from the testes and adrenals via castration (orchiectomy or LH-RH agonist administration) in combination with nonsteroidal antiandrogen preparation administration.
Though MAB has been a generally accepted method of treatment of progressive prostate cancer, whether it can improve long-term prognosis in comparison with castration alone has been a subject of recent discussion. According to the results of a meta-analysis recently performed, there is little difference in 2-year survival rate between MAB and monotherapy (castration or LH-RH agonist alone), though 5-year survival rate was significantly higher with MAB. However, since the difference in survival rate is small, it appears that true clinical benefit should be determined considering adverse reactions, QOL, and cost. At present, the results of further research demonstrating the validity of MAB are awaited. Recently, the results of a double-blind study that compared MAB monotherapy using bicalutamide as antiandrogen preparation with LH-RH agonist monotherapy were reported. Findings indicated a definite effect on time to progression.
Even when recurrence of cancer is observed, discontinuation of antiandrogen preparation alone can in some cases transiently inhibit the progress of disease (antiandrogen withdrawal syndrome). PSA decreased in 14 -60% and a clinical effect was observed in 0 -25% of patients with discontinuation of antiandrogen preparation, or combination with hydrocortisone. However, PSA reduction is reported to persist for only for 2 to 4 months, in general.
The above findings do not differ notably from those noted in the guidelines of the EAU or 3 NCI-PDQ. However, the EAU and NCI-PDQ guidelines take a somewhat negative stance regarding use of ADT in the treatment of LPC and LAPC.
The current issues in use of ADT concern the following 3 points: 1) Though their number is still small, clinical studies based on new concepts (effects of MAB and intermittent androgen blockade therapy, etc.) are being performed. Depending on the results of these studies, new conclusions regarding the role of ADT may be reached. 2)
ADT is generally employed in Japan to treat LPC and LAPC (Fig. 1) , and MAB is used in many cases (Fig. 2) . This tendency is definitely on the increase in the United States, as well (Fig. 3). 3) This choice of treatment is inconceivable if treatment method is selected according to the guidelines. Why, then, does it exist? USA CaPSURE data PADT is increasingly selected each year as a treatment against localized prostate cancer including the low risk and high risk groups. However, the ratio is still lower in comparison with the PADT ratio in Japan (Fig. 1 ).
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(III)
Factors involved in the determination of method of treatment According to Mulrow 3) , there are 3 types of factors that the physician and patient take into consideration in determining method of treatment ( . In these guidelines, the following 5 issues are discussed on the basis of newly published clinical study results:
( These issues are in addition important in assessing the usefulness of ADT in LPC and LAPC, the issue of greatest importance to use of ADT at present. The amount of literature judged to contribute to this update is very small during the relevant period, and is limited to 12 reports including those on RCT and reviews. Concerning issues (1) and (2) It is important to promote basic and clinical research based on the understanding that cure of prostate cancer is almost always possible with current ADT if progression to the hormone independent prostate cancer can be avoided.
